Work Here?
About Cardiosense
Industries
Data & Analytics
Enterprise Software
AI & Machine Learning
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$15.1M
Headquarters
Chicago, Illinois
Founded
2020
Overview
Cardiosense develops a non-invasive cardiac monitoring platform that uses wearable biometric sensors and artificial intelligence to analyze the full electromechanical behavior of each heartbeat. The system continuously tracks heart electrical signals and mechanical activity to provide early warnings of declining heart function. By selling the devices and offering a subscription-based analytics platform, Cardiosense targets hospitals and clinics to help healthcare teams prioritize at-risk patients and enable proactive interventions. Unlike traditional monitoring that relies on invasive methods or single-signal data, Cardiosense combines multiple data streams and AI-driven insights to detect signs of deterioration before symptoms appear. The company aims to improve patient outcomes by enabling timely care while the technology remains investigational under U.S. law.
Simplify's Take
What believers are saying
- CMS expanded remote patient monitoring reimbursement codes in 2025 directly fund heart failure management platforms.
- Heart failure readmission costs exceed $40 billion annually, creating strong payer incentives for early detection.
- EHR integration becoming standard requirement positions Cardiosense for rapid Epic and Cerner health system deployment.
What critics are saying
- CardiosensAI competitor predicts cardiac events 24 hours in advance with real-time AI, eroding first-mover advantage.
- FDA approval delays beyond investigational use block CardioTag commercialization and analytics subscription revenue streams.
- Burn rate exhaustion post-$15.1M Series A with no Series B evident forces dilution or shutdown.
What makes Cardiosense unique
- Multi-modal sensor fusion (ECG, SCG, PPG) achieves 92% accuracy correlating with invasive hemodynamic measurements.
- FDA Breakthrough Device designation for early heart failure detection algorithm enables expedited regulatory pathway.
- Physiological waveform AI platform generates actionable decompensation risk biomarkers, not passive data collection.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$15.1M
Meets
Industry Average
Funded Over
1 Rounds
Industry standards
Benefits
Hybrid Work Options
Relocation Assistance
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 5%2 year growth
↑ 2%Cardiosense Receives $15.1M Series A Round Back to HomeCHICAGO, IL, Cardiosense announced that it has raised $15.1 million in Series A funding.Cardiosense, a digital health company leveraging artificial intelligence and multi-sensor devices to enable early detection of cardiovascular disease, announced today that it has raised $15.1 million in Series A funding, co-led by Broadview Ventures and Hatteras Venture Partners, with participation from Laerdal Million Lives Fund, OSF Ventures, UnityPoint Health Ventures, and Portal Innovations. The capital will be used to support team expansion, accelerate product development, and fund an expansive heart failure study.Cardiosense is building a physiological waveform AI platform to develop predictive biomarkers to detect and manage cardiac disease. The Company has developed a suite of novel digital tools, multi-sensor devices, and analysis algorithms to detect early signs of cardiovascular disease, inform personalized therapy, and improve patient outcomes.(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page
There are no jobs for Cardiosense right now.
Find jobs on Simplify and start your career today
About Cardiosense
Industries
Data & Analytics
Enterprise Software
AI & Machine Learning
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$15.1M
Headquarters
Chicago, Illinois
Founded
2020
There are no jobs for Cardiosense right now.
Find jobs on Simplify and start your career today